IgniteData launches cutting edge data integration platform for clinical trials at Cambridge University Hospitals

, /PRNewswire/ -- IgniteData has announced a collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) and Cambridge University Hospitals NHS Foundation Trust (CUH) to launch its Archer tool for clinical data integration in an ongoing Phase 3 study sponsored by AstraZeneca. This collaboration marks a significant milestone in IgniteData's aim of transforming clinical trials through automation and digital innovation.

IgniteData's Archer tool is a technology platform that upholds the highest standards of data security and automates the data transfer process between hospital Electronic Health Records (EHRs) and sponsor Electronic Data Capture (EDCs), allowing researchers to focus more of their time on clinical research and less time on data entry. With its system-agnostic design, Archer integrates effortlessly with leading EHRs and EDCs to map a multitude of study variables and transfer several hundred data points per patient, resulting in significant time savings while ensuring the highest levels of data integrity and maintaining patient data privacy.

The collaboration between Cambridge University Hospitals, AstraZeneca, and IgniteData began in 2021, with AstraZeneca playing a key role in developing the Archer platform. After successful pilot studies at University College London Hospitals (UCLH) and Memorial Sloan Kettering Cancer Center (MSK), Archer is now being deployed in this pivotal study at Cambridge. All participating patients provided prior approval for the integration and use of their clinical data in the study. This collaboration underscores the commitment of both Cambridge University Hospitals and AstraZeneca to advancing clinical research through innovative technology. Dr. Wai Keong Wong, Clinical Director of Digital Transformation at CUH, expressed enthusiasm for the project, stating, "The integration of Archer into our EHR system represents a significant leap forward in how we conduct clinical trials. The automation of data capture not only enhances efficiency but also ensures the highest standards of data integrity, which is crucial for the success of our research and, ultimately, for patient outcomes."

Richard Yeatman, COO of IgniteData, added, "Our partnership with Cambridge University Hospitals and AstraZeneca is a testament to the power of collaboration in advancing clinical research. With Archer, we are laying the groundwork for a new era of digital innovation in clinical trials, one where data is transferred seamlessly, securely, and efficiently."

Looking Ahead
The data and insights gained from this live integration will inform future deployments of Archer across other NHS and European hospitals. This marks just the beginning of a broader initiative to scale this technology globally with approved sponsors, transforming the way clinical trials are conducted and accelerating the delivery of life-saving treatments to patients.

For more information about Archer and its role in modern clinical trials, visit IgniteData's website.

About IgniteData
IgniteData is the company shaping the future of clinical trials. Through its innovative digihealth platform, Archer, it is enhancing interoperability between Electronic Health Records (EHR) and key research applications such as Electronic Data Capture (EDC).

IgniteData is transforming the future of clinical trials through its cloud-based Virtual Research Assistant, Archer. A system-agnostic solution, Archer brings modern interoperability between EHR and key research systems, such as EDC, to provide seamless, secure transfer of clinically- validated data for clinical trials.

SOURCE IgniteData